Relaxivity of gadopentetate dimeglumine (Magnevist), gadobutrol (Gadovist), and gadobenate dimeglumine (MultiHance) in human blood plasma at 0.2, 1.5, and 3 Tesla

Investigative Radiology

Volumn 41, Issue 3, 2006, Pages 213-221

  Pintaske, Jörg ^a   Martirosian, Petros ^a   Graf, Hansjörg ^a   Erb, Gunter ^b   Lodemann, Klaus Peter ^b   Claussen, Claus D ^a   Schick, Fritz ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b Bracco Altana Pharma   (Germany)

Author keywords

Contrast media; Gadolinium; Relaxation rate; Relaxivity; Relaxometry

Indexed keywords

CONTRAST MEDIUM; GADOBENATE DIMEGLUMINE; GADOBUTROL; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE; DRUG DERIVATIVE; GADOBENIC ACID; GADOLINIUM DO3A BUTRIOL; GADOLINIUM-DO3A-BUTRIOL; MEGLUMINE; ORGANOMETALLIC COMPOUND;

ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG MONITORING; HUMAN; MEASUREMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAMETER; PRIORITY JOURNAL; COMPARATIVE STUDY; METHODOLOGY; STATISTICS;

CONTRAST MEDIA; GADOLINIUM DTPA; HUMANS; MAGNETIC RESONANCE IMAGING; MEGLUMINE; ORGANOMETALLIC COMPOUNDS; STATISTICS;

EID: 33646198875     PISSN: 00209996     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.rli.0000197668.44926.f7     Document Type: Article

References (35)

1. Kirchin MA, Runge VM. Contrast agents for magnetic resonance imaging: safety update. Top Magn Reson Imaging. 2003;14:426-435.
2. De Haën C, Cabrini M, Akhnana L, et al. Gadobenate dimeglumine 0.5 mM solution for injection (MultiHance®): pharmaceutical formulation and physicochemical properties of a new magnetic resonance imaging contrast medium. J Comput Assisted Tomogr. 1999;23(Suppl 1):S161-S168.
3. Balzer JO, Loewe C, Davis K, et al. Safety of contrast-enhanced MR angiography employing gadobutrol 1.0 M as contrast material. Eur Radiol. 2003;13:2067-2074.
4. Tweedle M. Physicochemical properties of gadoteridol and other magnetic resonance contrast agents. Invest Radiol. 1992;27(Suppl 1):2-6.
5. Tombach B, Heindel W. Value of 1.0 M gadolinium chelates: review of preclinical and clinical data on gadobutrol. Eur Radiol. 2002;12:1550-1556.
6. Spinazzi A, Lorusso V, Pirovano G, et al. Safety, tolerance, biodistribution and MR imaging enhancement of the liver with gadobenate dimeglumine. Acad Radiol. 1999;6:282-291.
7. Banci L, Bertini I, Luchinat C. Nuclear and Electron Relaxation. Weinheim, Germany: VCH Verlagsgesellschaft mbH; 1991:138.
8. Cavagna FM, Maggioni F, Castelli PM, et al. Gadolinium chelates with weak binding to serum proteins. A new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging. Invest Radiol. 1997;32:780-796.
9. Colosimo C, Ruscalleda J, Korves M, et al. Detection of intracranial metastases: a multi-center, intra-patient comparison of gadobenate dimeglumine-enhanced MRI with routinely used contrast agents at equal dose. Invest Radiol. 2001;36:72-81.
10. Knopp MV, Runge VM, Essig M, et al. Primary and secondary brain tumors at MR imaging: bicentric intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine. Radiology. 2004;230:55-64.
11. Colosimo C, Knopp MV, Barreau X, et al. A comparison of Gd-BOPTA and Gd-DOTA for contrast-enhanced MRI of intracranial tumours. Neuroradiology. 2004;46:655-665.
12. Colosimo C, Demaerel P, Tortori-Donati P, et al. Comparison of gadobenate dimeglumine (Gd-BOPTA) with gadopentetate dimeglumine (Gd-DTPA) for enhanced MR imaging of brain and spine tumors in pediatric subjects. Pediatr Radiol. 2005;35:501-510.
13. Essig M, Lodemann K-P, Le-Huu M, et al. Intra-individual comparison of gadobenate dimeglumine and gadobutrol for cerebral magnetic resonance perfusion imaging at 1.5 T. Invest Radiol. 2006;41:256-263.
14. Knopp MV, Bourne MW, Sardanelli F, et al. Gadobenate dimeglumine in contrast-enhanced magnetic resonance imaging of the breast: a dose response analysis and comparison with gadopentetate dimeglumine. Am J Roengenol. 2003;181:663-676.
15. Sardanelli F, Iozzelli A, Fausto A, et al. Breast vascular mapping with gadobenate Dimeglumine (Gd-BOPTA): association between cancer and ipsilateral increased vasculature. Radiology. 2005;235:791-797.
16. Pediconi F, Catalano C, Occhiato R, et al. Breast lesion detection and characterization at contrast-enhanced MR mammography: gadobenate dimeglumine versus gadopentetate dimeglumine. Radiology. 2005;237:45-56.
17. Schneider G, Maas R, Schultze Kool L, et al. Low-dose gadobenate dimeglumine versus standard dose gadopentetate dimeglumine for contrast-enhanced magnetic resonance imaging of the liver: an intra-individual crossover comparison. Invest Radiol. 2003;38:85-94.
18. Wersebe A, Wiskirehen J, Decker U, et al. Comparison of gadolinium-BOPTA and ferucarbotran-enhanced three-dimensional T1-weighted dynamic liver magnetic resonance imaging in the same patient. Invest Radiol. 2006;41:264-271.
19. Völk M, Strotzer M, Lenhart M, et al. Renal time-resolved MR angiography: quantitative comparison of gadobenate dimeglumine and gadopentetate dimeglumine with different doses. Radiology. 2001;220:484-488.
20. Knopp MV, Schoenberg SO, Rehm C, et al. Assessment of gadobenate dimeglumine (Gd-BOPTA) for MR angiography: phase I studies. Invest Radiol. 2002;37:706-715.
21. Wyttenbach R, Gianella S, Alerci M, et al. Prospective blinded evaluation of Gd-DOTA- versus Gd-BOPTA-enhanced peripheral MR angiography, as compared with digital subtraction angiography. Radiology. 2003;227:261-269.
22. Knopp MV, Giesel FL, von Tengg-Kobligk H, et al. Contrast-enhanced MR Angiography of the run-off fasculature: intraindividual comparison of gadobenate dimeglumine with gadopentetate dimeglumine. J Magn Reson Imaging. 2003;17:694-702.
23. Prokop M, Schneider G, Vanzulli A, et al. Contrast-enhanced MR angiography of the renal Arteries: blinded multicenter crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine. Radiology. 2005;234:399-408.
24. Kaldoudi E, Williams SCR. Relaxation time measurements in NMR imaging. Part 1: longitudinal relaxation time. Concepts Magn Reson. 1993;5:217-242.
25. MacFall JR, Wehrli FW, Breger RK, et al. Methodology for the measurement and analysis of relaxation times in proton imaging. Magn Reson Imaging. 1987;5:209-220.
26. Fram EK, Herfkens RJ, Johnson GA, et al. Rapid calculation of T1 using variable flip angle gradient refocusing imaging. Magn Reson Imaging. 1987;5:201-208.
27. 17O NMR relaxometric investigations on two gadolinium(III) DPTA-like chelates endowed with high binding affinity to human serum albumin. J Biol Inorg Chem. 1999;4:766-774.
28. Corot C, Violas X, Robert P, et al. Comparison of different types of blood pool agents (P792, MS325, USPIO) in a rabbit MR angiography-like protocol. Invest Radiol. 2003;38:311-319.
29. Caravan P, Cloutier NJ, Greenfield MT, et al. The interaction of MS-325 with human serum albumin and its effect on proton relaxation rates. J Am Chem Soc. 2002;124:3152-3162.
30. Vander Elst L, Maton F, Laurent S, et al. A multinuclear MR study of Gd-EOB-DPTA: comprehensive preclinical characterization of an organ specific MRI contrast agent. Magn Reson Med. 1997;38:604-614.
31. Vander Elst L, Chapelle F, Laurent S, et al. Stereospecific binding of MRI contrast agents to human serum albumin: the case of Gd-(S)-EOB-DPTA (Eovist) and its (R) isomer. J Biol Inorg Chem. 2001;6:196-200.
32. Giesel FL, von Tengg-Kobligk H, Wilkinson ID, et al. Influence of human serum albumin on longitudinal and transverse relaxation rates (R1 and R2) of magnetic resonance contrast agents. Invest Radiol. 2006;41:222-228.
33. Port M, Corot C, Violas X, et al. How to compare the efficiency of albumin-bound and nonalbumin-bound contrast agents in vivo: the concept of dynamic relaxivity. Invest Radiol. 2005;40:565-573.
34. Huppertz A, Rohrer M. Gadobutrol, a highly concentrated MR-imaging contrast agent: its physiochemical characteristics and the basis for its use in contrast-enhanced MR angiography and perfusion imaging. Eur Radiol. 2004;14(Suppl 5):M12-M18.
35. Rohrer M, Bauer H, Mintorovitch J, et al. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol. 2005;40:715-724.